Study on association of polymorphism of CYP450 2D6 with head and neck cancer and treatment response in patients receiving neoadjuvant chemotherapy paclitaxel, cisplatin, 5fu (TPF) followed by chemoradiation.

Simple item page
dc.contributor.authorKumar, Divyesh
dc.contributor.authorPant, Mohan Chand
dc.contributor.authorParmar, Devendra
dc.contributor.authorSingh, Sudhir
dc.contributor.authorBrahmabhatt, Madanlal
dc.date.accessioned2014-05-07T11:57:51Z
dc.date.available2014-05-07T11:57:51Z
dc.date.issued2014-04
dc.description.abstractBackground: Aims of this study were to study the association of genetic polymorphism in CYP450 2D6 in patients of locally advanced head and neck cancer, and try to assess a correlation between this polymorphism & response to treatment. Need of the study was to find out a possible genetic level explanation for the different response achieved in patients with similar histopathology, stage, exposure to carcinogen & ethnicity undergoing similar treatment. Methods: A study comprising of 150 patients & 150 controls was done to analyze the association between polymorphs of CYP450 2D6 with head & neck cancer and treatment response (TPFCTRT). Two cycles of TPF (paclitaxel-175mg/m2 D1, cisplatin 35mg/m2 D2-D3 and 5Fu 1gm/m2 D1-D3) were given followed by radiotherapy with concurrent cisplatin (40 mg/m2).The response to the treatment was assessed clinically, radiologically & by laryngoscopy-post treatment. Genotyping of the blood samples was done. Analysis of the association between genetic polymorphisms and risk of HNSCC was estimated by calculating crude odds ratio (OR). A P value of <0.05 was considered statistically significant. The statistical analysis was performed with the SPSS software package (version 11.0 for Windows; SPSS Chicago, IL). Results: Patients with CYP 2D6*1 showed good response to the therapy given, while CYP 2D6*4 and *10 were poor responders. Conclusion: There is a strong association of polymorphs of CYP 2D6 with occurrence of head and neck cancer. Response to treatment (TPFCT-RT) is polymorph graded. Our study thus provides an insight in to the concept of “Right therapy to the right patient”.en_US
dc.identifier.citationKumar Divyesh, Pant Mohan Chand, Parmar Devendra, Singh Sudhir, Brahmabhatt Madanlal. Study on association of polymorphism of CYP450 2D6 with head and neck cancer and treatment response in patients receiving neoadjuvant chemotherapy paclitaxel, cisplatin, 5fu (TPF) followed by chemoradiation. International Journal of Research in Medical Sciences. 2014 Apr-Jun; 2(2): 585-591.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/150681
dc.language.isoenen_US
dc.source.urihttps://www.msjonline.org/Volume2Issue2/Abstijrms20140541.phpen_US
dc.subjectPolymorphismen_US
dc.subjectCYP450 2D6en_US
dc.subjectChemoradiationen_US
dc.titleStudy on association of polymorphism of CYP450 2D6 with head and neck cancer and treatment response in patients receiving neoadjuvant chemotherapy paclitaxel, cisplatin, 5fu (TPF) followed by chemoradiation.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijrms2014v2n2p585.pdf
Size:
400.19 KB
Format:
Adobe Portable Document Format
Description:
Research article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
International Journal of Research in Medical Sciences